cannabidiol enema (IcBD-01) / CannaMore Biotechs - LARVOL DELTA

CannaMore Biotechs Announces Successful Completion of Phase 2a Clinical Trial for Cannabidiol-Based Treatment for Ulcerative Colitis (PRNewswire) - P2a | N=45 | NCT06353828 | Sponsor CannaMore Biotechs | "CannaMore Biotechs...is pleased to announce the successful completion of its Phase 2a clinical trial evaluating the safety and efficacy of a CBD-based patent protected formulation for patients with Ulcerative Colitis (UC)....Primary Endpoint Achieved: A significant number of patients demonstrated a reduction in Mayo scores, indicating a decrease in disease severity....Patient-Reported Outcomes (PRO): Most participants reported substantial improvements in their symptoms, including reduced abdominal pain and better overall well-being."

P2a data • Patient reported outcomes • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis